After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?

被引：2
作者：
Mackey, Tim K. [1 ,2 ,3 ,4 ]
Liang, Bryan A. [4 ]
机构：
[1] Univ Calif San Diego, Sch Med, Dept Med, Dept Anesthesiol,Div Global Publ Hlth, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Sch Med, Joint Masters Program Hlth Policy & Law, San Diego, CA 92103 USA
[3] Calif Western Sch Law, San Diego, CA USA
[4] Global Hlth Policy Inst, 8950 Villa La Jolla Dr,Ste A204, La Jolla, CA 92037 USA
来源：
MAYO CLINIC PROCEEDINGS | 2016年 / 91卷 / 06期
关键词：
DRUG-USE; 1ST-AMENDMENT; PHYSICIANS;
D O I：
10.1016/j.mayocp.2016.02.024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：701 / 706
页数：6
相关论文
共 19 条
[1]  
[Anonymous], 2013, HARVARD LAW REV, V127, P795
[2]   Forbidden and Permitted Statements about Medications - Loosening the Rules [J].
Avorn, Jerry ;
Sarpatwari, Ameet ;
Kesselheim, Aaron S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (10) :967-973
[3]   Repackaging Cigarettes - Will the Courts Thwart the FDA? [J].
Bayer, Ronald ;
Gostin, Lawrence ;
Marcus-Toll, Daniel .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2065-2067
[4]   Off label use-label off use? [J].
Boos, J .
ANNALS OF ONCOLOGY, 2003, 14 (01) :1-5
[5]   Off-Label Marketing and the First Amendment [J].
Boumil, Marcia M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (02) :103-105
[6]   US physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey [J].
Chen, Donna T. ;
Wynia, Matthew K. ;
Moloney, Rachael M. ;
Alexander, G. Caleb .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (11) :1094-1100
[7]   Association of Off-label Drug Use and Adverse Drug Events in an Adult Population [J].
Eguale, Tewodros ;
Buckeridge, David L. ;
Verma, Aman ;
Winslade, Nancy E. ;
Benedetti, Andrea ;
Hanley, James A. ;
Tamblyn, Robyn .
JAMA INTERNAL MEDICINE, 2016, 176 (01) :55-63
[8]  
Field Robert I, 2008, P T, V33, P220
[9]   Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities [J].
Gupta, Sandeep Kumar ;
Nayak, Roopa Prasad .
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (02) :88-92
[10]   FDA Regulation of Off-label Drug Promotion Under Attack [J].
Kesselheim, Aaron S. ;
Mello, Michelle M. ;
Avorn, Jerry .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (05) :445-446
12